Nasdaq:EYPT
EyePoint, Inc.
A clinical-stage biotech firm developing transformative gene therapies for age-related vision loss.
Key Metrics
Investment Thesis
Bull Case
Investors may view EyePoint as a high-risk, high-reward opportunity given its potential to capture a large market if its dry AMD therapies receive approval. The company's strategic partnerships provide near-term liquidity through upfront payments and milestones while building toward long-term royalty streams. A successful clinical trial could revalue the stock significantly by transforming it from a cash-burning biotech into a revenue-generating therapeutic platform.
Bear Case
The widening net loss of $-130.9M and negative operating cash flow suggest the company is burning through its balance sheet without clear near-term profitability. Investors should be wary of the substantial debt repayments and other investing outflows totaling over $600M which deplete resources needed for clinical trials. Without a proven track record of approved drugs, the stock remains speculative and vulnerable to dilution from common share issuances.
About EyePoint, Inc.
EyePoint, Inc. (EYPT) is a clinical-stage biotechnology company focused on developing novel therapeutics for age-related vision diseases, primarily targeting dry age-related macular degeneration (AMD). The company operates primarily in the United States and serves patients suffering from significant visual impairment that current treatments cannot address. Revenue generation relies heavily on product development agreements and grants rather than traditional commercial sales, with a substantial portion of cash flow directed toward research and development.
Analysis
Management Discussion
Financial performance shows continued heavy investment in innovation with research and development expenses reaching $132.9M, alongside share-based compensation of $36.7M reflecting ongoing talent acquisition. While revenue declined slightly to $43.3M compared to the prior year, net income loss widened to $-130.9M, indicating that cash burn remains high despite modest top-line growth from product development deals. The company ended the period with $99.7M in cash and equivalents but still reported a negative change in cash of $-181.6M due to net investing outflows.
Industry Overview
The ophthalmology sector is rapidly evolving with gene therapies offering curative potential for previously untreatable conditions like dry AMD and inherited retinal diseases. Competition is intensifying as major pharmaceutical companies enter the space, though small-cap biotechs often move faster in early-stage innovation. Regulatory hurdles remain high, requiring extensive Phase 2 and Phase 3 trials to demonstrate safety and efficacy before market entry.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $41.4M | $46.0M | $43.3M |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $41.4M | $46.0M | $43.3M |
| Operating Expenses | $141.0M | $121.1M | $189.1M |
| Operating Income | $-99.6M | $-75.1M | $-145.9M |
| R&D | $49.6M | $64.7M | $132.9M |
| G&A | $34.8M | $40.1M | $52.4M |
| Marketing | $25.5M | $11.7M | $131.0K |
| Stock-Based Comp | $14.2M | $12.1M | $36.7M |
| D&A | — | — | $1.5M |
| Depreciation | $396.0K | $464.0K | $1.5M |
| Amortization | $2.0M | $0 | — |
| Other OpEx | $31.1M | $4.6M | $3.7M |
| Non-Operating Income | $-2.6M | $4.4M | $15.1M |
| Interest Expense | $3.2M | $1.2M | — |
| Pre-Tax Income | $-102.3M | $-70.7M | $-130.8M |
| Income Tax | $0 | $83.0K | $90.0K |
| Continuing Ops | $-102.3M | $-70.8M | $-130.9M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-102.3M | $-70.8M | $-130.9M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-102.3M | $-70.8M | $-130.9M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $172.8M | $344.8M | $383.3M |
| Cash & Equivalents | $95.6M | $281.3M | $99.7M |
| Marketable Securities | $48.9M | $49.8M | $271.2M |
| Inventory | $2.9M | $3.9M | $2.3M |
| Prepaid Expenses | $9.9M | $9.0M | $9.5M |
| Other Current Assets | $15.5M | $805.0K | $607.0K |
| Long-Term Assets | $7.5M | $10.4M | $35.2M |
| PP&E (Net) | $1.4M | $5.3M | $8.2M |
| Operating Leases | $6.0M | $5.0M | $21.0M |
| Other LT Assets | $150.0K | $150.0K | $6.0M |
| Total Assets | $180.4M | $355.2M | $418.5M |
| Current Liabilities | $34.5M | $63.3M | $49.0M |
| Accounts Payable | $5.9M | $6.5M | $11.7M |
| Current Leases | $543.0K | $563.0K | $1.2M |
| Other Current Liab | $11.7M | $38.7M | $18.0M |
| Long-Term Liabilities | $49.5M | $25.6M | $32.9M |
| Long-Term Debt | $29.3M | — | — |
| LT Operating Leases | $6.0M | $4.9M | $21.9M |
| Other LT Liab | $14.2M | $20.7M | $11.1M |
| Total Liabilities | $84.0M | $88.9M | $82.0M |
| Shareholders' Equity | $96.4M | $266.3M | $336.5M |
| Retained Earnings | $-671.4M | $-742.1M | $-873.0M |
| AOCI | $786.0K | $864.0K | $1.0M |
| Total L&E | $180.4M | $355.2M | $418.5M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-102.3M | $-70.8M | $-130.9M |
| Non-Cash Adjustments | $33.5M | $39.5M | $25.1M |
| Working Capital Changes | $3.8M | $33.2M | $-20.4M |
| Cash from Operations | $-65.0M | $1.9M | $-126.2M |
| Capital Expenditures | $2.1M | $3.5M | $4.1M |
| Cash from Investing | $-17.3M | $-3.3M | $-219.4M |
| Debt Issuances | $30.0M | $0 | — |
| Debt Repayments | $38.2M | $30.0M | $0 |
| Cash from Financing | $-690.0K | $187.1M | $164.0M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-83.0M | $185.6M | $-181.6M |
| Beginning Cash | $178.7M | $95.8M | $281.4M |
| Ending Cash | $95.8M | $281.4M | $99.9M |
Frequently Asked Questions
How does EyePoint, Inc. make money?
The company's revenue is derived from product development agreements (PDAs) where partners advance its drug candidates in exchange for upfront payments, milestones, and royalties. Additionally, income comes from government grants and research contracts supporting its early-stage clinical programs for treating dry AMD and diabetic macular edema.
What are the main risks for EYPT?
The company faces significant commercialization risk as its drug candidates are still in clinical trials with no guarantee of regulatory approval or market success. EyePoint carries substantial cash burn, evidenced by negative operating cash flow and a large retained earnings deficit, raising concerns about liquidity if financing dries up. Failure to achieve key clinical milestones could result in total loss of invested capital and potential dilution from new equity issuances.
What is EYPT's competitive advantage?
EyePoint possesses a proprietary gene therapy platform capable of delivering therapeutic genes to the eye to treat underlying genetic causes of vision loss. The company holds robust intellectual property portfolios in ophthalmology that provide first-mover potential for approved therapies. Its partnership strategy allows it to leverage external capital and expertise while maintaining control over its core asset development.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.